Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.

Lin G, Li C, Li PS, Fang WZ, Xu HP, Gong YH, Zhu ZF, Hu Y, Liang WH, Chu Q, Zhong WZ, Wu L, Wang HJ, Wang ZJ, Li ZM, Lin J, Guan YF, Xia XF, Yi X, Miao Q, Wu B, Jiang K, Zheng XB, Zhu WF, Zheng XL, Huang PS, Xiao WJ, Hu D, Zhang LF, Fan XR, Mok TSK, Huang C.

Ann Oncol. 2020 Apr;31(4):517-524. doi: 10.1016/j.annonc.2020.01.014. Epub 2020 Jan 24.

PMID:
32151507
2.

Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study.

Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Mendoza-Naranjo A, Mok TSK.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48. doi: 10.1093/annonc/mdz063.003. No abstract available.

3.

IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations.

Reck M, Jotte R, Mok TSK, Lim DW, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Nishio M, Lee A, Shankar G, Yu W, Socinski MA.

Ann Oncol. 2019 Apr;30 Suppl 2:ii48-ii49. doi: 10.1093/annonc/mdz063.002. No abstract available.

4.

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, de Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Caglevic C, Karaszewska B, Dang T, Yin L, Penrod J, Lopes G.

Ann Oncol. 2019 Apr;30 Suppl 2:i38. doi: 10.1093/annonc/mdz063. No abstract available.

5.

ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.

Chan OSH, Lam KC, Li JYC, Choi FPT, Wong CYH, Chang ATY, Mo FKF, Wang K, Yeung RMW, Mok TSK.

Lung Cancer. 2020 Apr;142:41-46. doi: 10.1016/j.lungcan.2020.02.002. Epub 2020 Feb 11.

PMID:
32088604
6.

Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S.

Ann Oncol. 2019 May;30(5):863-870. doi: 10.1093/annonc/mdy474. Epub 2019 Dec 4. No abstract available.

PMID:
31987360
7.

Twenty-five years of Respirology: Advances in lung cancer.

Ang MK, Mok TSK.

Respirology. 2020 Jan;25(1):26-31. doi: 10.1111/resp.13745. Review. No abstract available.

8.

Quantifying the benefit of non-small-cell lung cancer immunotherapy - Authors' reply.

Mok TSK, Zhang J, Lopes G.

Lancet. 2019 Nov 23;394(10212):1904-1905. doi: 10.1016/S0140-6736(19)32605-4. No abstract available.

PMID:
31777386
9.

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC.

Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F.

J Thorac Oncol. 2020 Mar;15(3):324-343. doi: 10.1016/j.jtho.2019.10.022. Epub 2019 Nov 13. Review.

PMID:
31733357
10.

Ambient fine particulate matter inhibits 15-lipoxygenases to promote lung carcinogenesis.

Li MY, Liu LZ, Li W, Ng CSH, Liu Y, Kong AWY, Zhao Z, Wang S, Qi H, Jia H, Yang S, Du J, Long X, Ho RLK, Chak ECW, Wan IYP, Mok TSK, Underwood MJ, Gali NK, Ning Z, Chen GG.

J Exp Clin Cancer Res. 2019 Aug 16;38(1):359. doi: 10.1186/s13046-019-1380-z.

11.

Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer.

Lee VHF, Mok TSK, Goto Y, Hsue VCC, Yang L, Jiang Y, Leung DKC, Lau KS, Tse PY.

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e1-e9. doi: 10.1016/j.clon.2019.07.014. Epub 2019 Jul 30.

PMID:
31375307
12.

Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer.

Corral J, Mok TS, Nakagawa K, Rosell R, Lee KH, Migliorino MR, Pluzanski A, Linke R, Devgan G, Tan W, Quinn S, Wang T, Wu YL.

Future Oncol. 2019 Aug;15(24):2795-2805. doi: 10.2217/fon-2019-0299. Epub 2019 Jul 17.

13.

Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.

Lau SCM, Batra U, Mok TSK, Loong HH.

Drugs. 2019 Jun;79(8):823-831. doi: 10.1007/s40265-019-01115-y. Review.

PMID:
31069718
14.

The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.

Chan AW, Chau SL, Tong JH, Chow C, Kwan JSH, Chung LY, Lung RW, Tong CY, Tin EK, Law PP, Law WT, Ng CSH, Wan IYP, Mok TSK, To KF.

J Thorac Oncol. 2019 Jul;14(7):1213-1222. doi: 10.1016/j.jtho.2019.03.021. Epub 2019 Apr 9.

PMID:
30978501
15.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators.

Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.

PMID:
30955977
16.

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group.

Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.

PMID:
30922878
17.

Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer.

Heigener DF, Kerr KM, Laing GM, Mok TSK, Moiseyenko FV, Reck M.

Clin Cancer Res. 2019 Aug 15;25(16):4881-4887. doi: 10.1158/1078-0432.CCR-18-1894. Epub 2019 Mar 25. Review.

PMID:
30910855
18.

A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy.

Molassiotis A, Suen LKP, Cheng HL, Mok TSK, Lee SCY, Wang CH, Lee P, Leung H, Chan V, Lau TKH, Yeo W.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419836501. doi: 10.1177/1534735419836501.

19.

Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.

Zhou Q, Wu YL, Corral J, Nakagawa K, Garon EB, Sbar EI, Wang T, Sandin R, Noonan K, Gernhardt D, Mok TS.

Future Oncol. 2019 May;15(13):1481-1491. doi: 10.2217/fon-2018-0944. Epub 2019 Mar 6.

PMID:
30839234
20.

Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin.

Sun K, Jiang P, Cheng SH, Cheng THT, Wong J, Wong VWS, Ng SSM, Ma BBY, Leung TY, Chan SL, Mok TSK, Lai PBS, Chan HLY, Sun H, Chan KCA, Chiu RWK, Lo YMD.

Genome Res. 2019 Mar;29(3):418-427. doi: 10.1101/gr.242719.118.

21.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275. No abstract available. Erratum in: Ann Oncol. 2019 May;30(5):863-870.

22.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.

Ann Oncol. 2018 Oct;29 Suppl 4:iv192-iv237. doi: 10.1093/annonc/mdy275. Epub 2020 Jan 7. Review. No abstract available.

PMID:
32169226
23.

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer.

Loong HH, Kwan SS, Mok TS, Lau YM.

Curr Treat Options Oncol. 2018 Sep 29;19(11):58. doi: 10.1007/s11864-018-0570-9. Review.

PMID:
30267319
24.

Novel method for rapid identification of micropapillary or solid components in early-stage lung adenocarcinoma.

Zhao ZR, Lau RWH, Long H, Mok TSK, Chen GG, Underwood MJ, Ng CSH.

J Thorac Cardiovasc Surg. 2018 Dec;156(6):2310-2318.e2. doi: 10.1016/j.jtcvs.2018.07.054. Epub 2018 Aug 2.

PMID:
30180981
25.

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.

Wang Z, Zhao J, Wang G, Zhang F, Zhang Z, Zhang F, Zhang Y, Dong H, Zhao X, Duan J, Bai H, Tian Y, Wan R, Han M, Cao Y, Xiong L, Liu L, Wang S, Cai S, Mok TSK, Wang J.

Cancer Res. 2018 Nov 15;78(22):6486-6496. doi: 10.1158/0008-5472.CAN-18-1814. Epub 2018 Aug 31.

26.

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK.

J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.

PMID:
30059262
27.

Is the LENT Score Already Outdated?

Rozman A, Mok TSK.

Respiration. 2018;96(4):303-304. doi: 10.1159/000491678. Epub 2018 Jul 26. No abstract available.

28.

Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.

Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall F, Mok TS, Wu YL, Pestova K, Wilner KD, Polli A, Paolini J, Lanzalone S, Green S, Camidge DR.

Ann Oncol. 2018 Sep 1;29(9):1964-1971. doi: 10.1093/annonc/mdy242.

29.

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.

Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, Wilner KD, Tang Y, Masters ET, Selaru P, Mok TS.

J Thorac Oncol. 2018 Oct;13(10):1539-1548. doi: 10.1016/j.jtho.2018.06.012. Epub 2018 Aug 14.

30.

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

31.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

32.

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL.

J Clin Oncol. 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4.

PMID:
29864379
33.

Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.

Loong HH, Raymond VM, Shiotsu Y, Chua DTT, Teo PML, Yung T, Skrzypczak S, Lanman RB, Mok TSK.

Clin Lung Cancer. 2018 Sep;19(5):e601-e608. doi: 10.1016/j.cllc.2018.04.022. Epub 2018 May 7.

PMID:
29807856
34.

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS.

J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. Epub 2018 May 16.

PMID:
29768118
35.

Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.

Chan AWH, Tong JHM, Kwan JSH, Chow C, Chung LY, Chau SL, Lung RWM, Ng CSH, Wan IYP, Mok TSK, To KF.

Mod Pathol. 2018 Sep;31(9):1381-1390. doi: 10.1038/s41379-018-0053-3. Epub 2018 Apr 30.

36.

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy.

Shukla ND, Salahudeen AA, Taylor GA, Ramalingam SS, Vokes EE, Goss GD, Decker RH, Kelly K, Scagliotti GV, Mok TS, Wakelee HA.

Clin Lung Cancer. 2018 Sep;19(5):377-386. doi: 10.1016/j.cllc.2018.03.004. Epub 2018 Mar 17. Review.

37.

Overview of current systemic management of EGFR-mutant NSCLC.

Hsu WH, Yang JC, Mok TS, Loong HH.

Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9. doi: 10.1093/annonc/mdx702. Review.

38.

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Ramón Y Cajal S, Frias A, Cao P, Rosell R.

EBioMedicine. 2018 Mar;29:112-127. doi: 10.1016/j.ebiom.2018.02.001. Epub 2018 Feb 5.

39.

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI.

Cheong HT, Xu F, Choy CT, Hui CWC, Mok TSK, Wong CH.

Oncol Lett. 2018 Jan;15(1):901-907. doi: 10.3892/ol.2017.7377. Epub 2017 Nov 9.

40.

Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.

Wu YL, Mok TS.

Lancet Oncol. 2018 Jan;19(1):e5. doi: 10.1016/S1470-2045(17)30924-5. No abstract available.

PMID:
29304363
41.

Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas.

Li L, Xu J, Qiu G, Ying J, Du Z, Xiang T, Wong KY, Srivastava G, Zhu XF, Mok TS, Chan AT, Chan FK, Ambinder RF, Tao Q.

Theranostics. 2018 Jan 1;8(1):61-77. doi: 10.7150/thno.20893. eCollection 2018.

42.

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC.

Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13. Review.

PMID:
29290252
43.

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.

Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C.

Clin Drug Investig. 2018 Apr;38(4):319-331. doi: 10.1007/s40261-017-0611-3.

44.

De-novo and acquired resistance to immune checkpoint targeting.

Syn NL, Teng MWL, Mok TSK, Soo RA.

Lancet Oncol. 2017 Dec;18(12):e731-e741. doi: 10.1016/S1470-2045(17)30607-1. Review.

PMID:
29208439
45.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T.

Ann Oncol. 2017 Nov 1;28(11):2698-2706. doi: 10.1093/annonc/mdx419.

46.

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC.

J Clin Oncol. 2017 Dec 20;35(36):4027-4034. doi: 10.1200/JCO.2017.73.9250. Epub 2017 Oct 2.

PMID:
28968167
47.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS.

Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.

PMID:
28958502
48.

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.

Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, Fan X, Zhu W, Huang Y, Lin X, Jiang K, Hu D, Chen X, Huang P, Lin G.

J Thorac Oncol. 2017 Oct;12(10):1536-1543. doi: 10.1016/j.jtho.2017.07.015. Epub 2017 Jul 24.

49.

A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.

Chan SL, Yeo W, Mo F, Chan AWH, Koh J, Li L, Hui EP, Chong CCN, Lai PBS, Mok TSK, Yu SCH.

Cancer. 2017 Oct 15;123(20):3977-3985. doi: 10.1002/cncr.30825. Epub 2017 Jun 22.

50.

Osimertinib in EGFR T790M-Positive Lung Cancer.

Mok TS, Wu YL, Papadimitrakopoulou VA.

N Engl J Med. 2017 May 18;376(20):1993-4. doi: 10.1056/NEJMc1703339. No abstract available.

PMID:
28514610

Supplemental Content

Support Center